National Cancer Institute to Grant Exclusive Patent License to Aspyrian Therapeutics for Antibody-Drug Conjugate in PhotoImmunoTherapy

Summary

The National Institutes of Health is considering granting an exclusive patent license to Aspyrian Therapeutics to develop an antibody-drug conjugate for use in photoimmunotherapy, a treatment approach for cancer.